Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Clinical trial NCT01892371 · COMPLETED

Trial details

NCT number: NCT01892371
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

FLT3 Gene Mutation Negative FLT3 Internal Tandem Duplication Positive Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Chronic Myelomonocytic Leukemia Refractory Myelodysplastic Syndrome

Start date: 2013-11-12
Primary completion: 2023-02-07
Enrollment: 73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.